FDA Class II Recall: Westminster Pharmaceuticals' Metoprolol Tartrate Contaminated with N-nitroso-metoprolol
Westminster Pharmaceuticals LLC has initiated a Class II recall for Metoprolol Tartrate Tablets due to N-nitroso-metoprolol exceeding the Acceptable Daily Intake. This nationwide recall impacts 4,456 bottles, signaling critical supply chain vulnerabilities and heightened regulatory scrutiny on nitrosamine impurities, requiring immediate action from procurement and regulatory teams.
FDA Class II Recall: Metoprolol Tartrate Contamination by N-nitroso-metoprolol
Westminster Pharmaceuticals LLC has initiated a voluntary, firm-initiated Class II recall for specific batches of Metoprolol Tartrate Tablets, USP, 100 mg. This critical action, designated recall number D-0582-2025, commenced on August 6, 2025, following the discovery of N-nitroso-metoprolol at levels exceeding the established Acceptable Daily Intake (ADI). The affected product, packaged in 1000-count bottles with NDC 69367-355-10, is a human prescription drug administered orally, widely used for conditions such as hypertension, angina pectoris, and heart failure. The presence of nitrosamine impurities above safety thresholds represents a significant Current Good Manufacturing Practice (CGMP) deviation, posing a potential health risk to patients. For procurement directors, this means an immediate need to quarantine and return all affected inventory, specifically batches R56240011 (Exp Date: 2/28/26), R56240021, R56240031 (Exp Date: 3/31/26), R56240041, R56240051, R56240061 (Exp Date: 4/30/26), and R56240071 (Exp Date: 7/31/26). The recall's ongoing status, as of the August 20, 2025 report date, necessitates continuous monitoring of FDA communications to ensure full compliance and minimize business disruption.
Supply Chain Vulnerabilities: Impact of Metoprolol Tartrate Recall on Procurement and Distribution
This Class II recall by Westminster Pharmaceuticals LLC, based in Nashville, TN, highlights critical vulnerabilities within the global pharmaceutical supply chain. The recalled Metoprolol Tartrate product was manufactured by Renata PLC (General Plant -2) located in Noyapara, Bhawal Mirzapur, Rajendrapur, Gazipur, 1700 Bangladesh, and subsequently distributed nationwide across the USA by Westminster. A total of 4,456 1000-count bottles are subject to this recall, representing a substantial volume of a commonly prescribed cardiovascular medication. For supply chain VPs and business development executives, this event underscores the imperative for rigorous due diligence on contract manufacturers, particularly those in international jurisdictions. The nationwide distribution pattern means that healthcare providers and pharmacies across the United States are directly impacted, requiring efficient communication and recall logistics from Westminster Pharmaceuticals. Procurement teams must immediately assess their inventory of Metoprolol Tartrate, identify any stock originating from Renata PLC via Westminster, and initiate return procedures. Furthermore, this incident necessitates a comprehensive review of supplier qualification processes to ensure that all manufacturers, regardless of geographic location, adhere to stringent CGMP standards and robust impurity testing protocols, especially concerning nitrosamine formation pathways. Failure to act decisively can lead to significant financial losses from returned product, reputational damage, and potential supply shortages for a vital medication.
Mitigating Nitrosamine Risk: Strategic Implications for Pharmaceutical Quality and Compliance
The detection of N-nitroso-metoprolol above the Acceptable Daily Intake in Metoprolol Tartrate Tablets is not an isolated incident but rather indicative of a persistent industry-wide challenge with nitrosamine impurities. This recall reinforces the FDA's heightened scrutiny on these probable human carcinogens across various drug classes. For regulatory affairs heads, this event mandates an immediate re-evaluation of all product portfolios for potential nitrosamine contamination risks, particularly for active pharmaceutical ingredients (APIs) and finished drug products manufactured using processes susceptible to nitrosamine formation. The FDA's classification of this as an 'ongoing' recall signals that Westminster Pharmaceuticals and its manufacturing partner, Renata PLC, will face continued regulatory oversight. Companies must proactively implement enhanced quality control measures, including comprehensive risk assessments, robust analytical testing methods, and process modifications to prevent and control nitrosamine impurities. This proactive approach is crucial to avoid similar CGMP deviations and subsequent recalls, which can lead to significant market disruption and patient safety concerns. The broader regulatory landscape, as evidenced by recent parallel events such as Essential Wellness Pharma's recall for sterility issues, indicates a sustained focus on manufacturing quality and patient safety. Investing in advanced impurity profiling and supplier auditing is no longer optional but a strategic imperative to maintain market access and ensure uninterrupted supply of critical medications like Metoprolol Tartrate.